Article
Oncology
Hikmat H. Assi, Chihunt Wong, Kimberly A. Tipton, Li Mei, Ken Wong, Jennifer Razo, Chanty Chan, Bruce Howng, Jason Sagert, Michael Krimm, Linnea Diep, Andrew Jang, Margaret T. Nguyen, Nicole Lapuyade, Victoria Singson, Ruth Villanueva, Madan Paidhungat, Shouchun Liu, Vangipuram Rangan, Olga Vasiljeva, James W. West, Jennifer H. Richardson, Bryan Irving, Dylan Daniel, Marcia Belvin, W. Michael Kavanaugh
Summary: Using protease-activatable antibody prodrugs (Pb-Tx) to locally inhibit PD-1/PD-L1 can reduce systemic immune toxicity while eliciting potent anti-tumor immune responses.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Multidisciplinary Sciences
Changsheng Huang, Shengxiang Ren, Yaqi Chen, Anyi Liu, Qi Wu, Tao Jiang, Panjing Lv, Da Song, Fuqing Hu, Jingqing Lan, Li Sun, Xue Zheng, Xuelai Luo, Qian Chu, Keyi Jia, Yan Li, Jun Wang, Caicun Zou, Junbo Hu, Guihua Wang
Summary: This research discovered that PD-L1 K162 was methylated by SETD7 and demethylated by LSD2. Additionally, PD-L1 K162 methylation controlled the PD1/PD-L1 interaction and significantly enhanced the suppression of T cell activity in controlling cancer immune surveillance. The study demonstrated that PD-L1 hypermethylation was the key mechanism for anti-PD-L1 therapy resistance, identified PD-L1 K162 methylation as a negative predictive marker for anti-PD-1 treatment in patients with non-small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti-PD-(L)1 therapy sensitivity.
Article
Oncology
Sophia Z. Shalhout, Kevin S. Emerick, Howard L. Kaufman, Ann W. Silk, Manisha Thakuria, David M. Miller
Summary: Merkel cell carcinoma is a rare but highly aggressive skin cancer associated with UV exposure and viral infection. Immune checkpoint inhibitors have shown some clinical benefit in the treatment of advanced MCC, but resistance to these drugs remains a challenge. There is a lack of studies evaluating second-line systemic therapy for patients with resistance to anti-PD-(L)1 therapy.
JOURNAL OF IMMUNOTHERAPY
(2022)
Review
Chemistry, Medicinal
Qi Zhang, Chenying Yang, Xingsu Gao, Ju Dong, Caiyun Zhong
Summary: This article discusses the role of immune checkpoint blockade in cancer treatment and explores the modulation of immune checkpoint proteins by phytochemicals and their combination effects with immune checkpoint inhibitors in various malignancies.
PHYTOTHERAPY RESEARCH
(2023)
Article
Oncology
Nicholas D. Klemen, Colin M. Court, Maria Clara Fernandes, Henry S. Walch, Walid K. Chatila, Lily Saadat, Steven Maron, Chris Crane, Jinru Shia, Andrea Cercek, Mithat Gonen, Nikolaus D. Schultz, Julio Garcia Aguilar, William R. Jarnagin, Michael D'Angelica
Summary: The study found that oligoprogression, a common pattern of failure after ICI, can be effectively managed with local therapy, while it may not be necessary to consolidate stable disease for selected patients. Further research is essential for better defining management algorithms and exploring heterogeneity in response patterns.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Xiaoxiang Zhou, Zhuoran Yao, Hua Bai, Jianchun Duan, Zhijie Wang, Xin Wang, Xue Zhang, Jiachen Xu, Kailun Fei, Zhen Zhang, Fengwei Tan, Qi Xue, Shugeng Gao, Yibo Gao, Jie Wang, Jie He
Summary: This study comprehensively investigated the incidences and profiles of treatment-related adverse events in different PD-1 or PD-L1 inhibitor-based combination therapies. Results showed variations in the incidence and profiles of adverse events among different combination therapies, providing essential reference for clinicians in routine practice of cancer care.
Article
Oncology
Daniel J. Olson, Zeynep Eroglu, Bruce Brockstein, Andrew S. Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, Mario Velasco, Jose Lutzky, Emily Higgs, Riyue Bao, Timothy C. Carll, Brian Labadie, Thomas Krausz, Yuanyuan Zha, Theodore Karrison, Vernon K. Sondak, Thomas F. Gajewski, Nikhil Khushalani, Jason J. Luke
Summary: This study is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
James A. Hutchinson, Katharina Kronenberg, Paloma Riquelme, Juergen J. Wenzel, Gunther Glehr, Hannah-Lou Schilling, Florian Zeman, Katja Evert, Martin Schmiedel, Marion Mickler, Konstantin Drexler, Florian Bitterer, Laura Cordero, Lukas Beyer, Christian Bach, Josef Koestler, Ralph Burkhardt, Hans J. Schlitt, Dirk Hellwig, Jens M. Werner, Rainer Spang, Barbara Schmidt, Edward K. Geissler, Sebastian Haferkamp
Summary: The study reveals that pre-treatment expansion of CD4(+) effector memory T cells is a risk factor for hepatitis following immune checkpoint blockade therapy, and suggests possibilities for prevention or avoidance. The findings illustrate how clinical reactions after cancer therapy can be shaped by pathogen exposure, leading to therapeutic innovations.
NATURE COMMUNICATIONS
(2021)
Editorial Material
Oncology
James W. Smithy, Jason J. Luke
Summary: A retrospective analysis revealed that higher pretreatment tissue densities of CD16(+) macrophages were correlated with clinical benefit from combined CTLA-4 and PD-1 blockade in patients with unresectable melanoma. This biomarker could potentially be used in selecting immune checkpoint inhibitor regimens with further validation.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, Research & Experimental
Yujeong Moon, Man Kyu Shim, Jiwoong Choi, Suah Yang, Jinseong Kim, Wan Su Yun, Hanhee Cho, Jung Yeon Park, Yongju Kim, Joon-Kyung Seong, Kwangmeyung Kim
Summary: In this study, the researchers propose a new strategy to enhance cancer immunotherapy by using anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs). The PD-NPs are taken up by cancer cells and release the drug, resulting in the disruption of immune-suppressing pathways and the enhancement of T lymphocyte immune responses. The results show that PD-NPs accumulate in tumor tissues and recruit a large amount of immune cells, leading to effective antitumor effects. This strategy has the potential to overcome the toxicity and low response rate issues in current cancer immunotherapy.
Article
Oncology
Lingyi Fu, Sen Li, WeiWei Xiao, Kuai Yu, Shuo Li, Sujing Yuan, Jianfei Shen, Xingjun Dong, Ziqian Fang, Jianeng Zhang, Siyu Chen, Wende Li, Hua You, Xiaojun Xia, Tiebang Kang, Jing Tan, Gong Chen, An-Kui Yang, YuanHong Gao, Penghui Zhou
Summary: The study demonstrated that Dgka mediates T-cell dysfunction during anti-PD-1 therapy. Inhibiting Dgka can delay T-cell exhaustion and enhance the efficacy of anti-PD-1 therapy. Additionally, the expression of DGKA in cancer cells promotes tumor growth via the AKT signaling pathway.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Oncology
Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, David W. Vredevoogd, Elisa A. Rozeman, Sofia Ibanez Molero, Beaunelle de Bruijn, Paulien Cornelissen-Steijger, Aida Shahrabi, Martin Del Castillo Velasco-Herrera, Ji-Ying Song, Maarten A. Ligtenberg, Roelof J. C. Kluin, Thomas Kuilman, Petra Ross-Macdonald, John B. A. G. Haanen, David J. Adams, Christian U. Blank, Daniel S. Peeper
Summary: This study used different signatures to predict the response and benefits of anti-PD-1 and anti-CTLA-4 treatments in melanoma patients, identifying which patients need combination immune checkpoint blockade therapy.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Hyun Ae Jung, Sehhoon Park, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
Summary: This study found that continuing pembrolizumab with chemotherapy did not improve survival in patients with non-small cell lung cancer (NSCLC) who had previously failed PD-1/PD-L1 inhibitor therapy. However, in a subgroup with high expression of PD-L1 in tumor cells and favorable clinical outcomes to prior PD-1/PD-L1 inhibitor, the pembrolizumab-chemotherapy arm showed a higher 24-month survival rate.
CLINICAL CANCER RESEARCH
(2022)
Article
Chemistry, Multidisciplinary
Jingmei Pan, Xilin Li, Binfen Shao, Funeng Xu, Xuehui Huang, Xing Guo, Shaobing Zhou
Summary: A nanocarrier that achieves self-blockade of PD-L1 in tumor cells and a detection kit to quantitatively measure the binding rate of PD-1/PD-L1 have been developed, improving the efficacy of PD-1/PD-L1 self-blocking therapy.
ADVANCED MATERIALS
(2022)
Article
Chemistry, Multidisciplinary
Weijing Yang, Meng Zhang, Jinjie Zhang, Yanlong Liu, Jie Ning, Jing Yang, Zhenzhong Zhang, Lin Hou, Xiaoyuan Chen
Summary: Targeting pre-activated T cells with immune checkpoint blockade through sequential therapy enhances immune response and improves antitumor activity.
Review
Oncology
Claire F. Friedman, Martee L. Hensley
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2018)
Article
Oncology
Samuel Rosner, Erica Kwong, Alexander N. Shoushtari, Claire F. Friedman, Allison S. Betof, Mary Sue Brady, Daniel G. Coit, Margaret K. Callahan, Jedd D. Wolchok, Paul B. Chapman, Katherine S. Panageas, Michael A. Postow
Article
Oncology
Alexander N. Shoushtari, Claire F. Friedman, Pedram Navid-Azarbaijani, Michael A. Postow, Margaret K. Callahan, Parisa Momtaz, Katherine S. Panageas, Jedd D. Wolchok, Paul B. Chapman
Article
Oncology
Julia L. Boland, Qin Zhou, Madhuri Martin, Margaret K. Callahan, Jason Konner, Roisin E. O'Cearbhaill, Claire F. Friedman, William Tew, Vicky Makker, Rachel N. Grisham, Martee L. Hensley, Nicholas Zecca, Alexia E. Iasonos, Alexandra Snyder, David M. Hyman, Paul Sabbatini, Carol Aghajanian, Karen A. Cadoo, Dmitriy Zamarin
GYNECOLOGIC ONCOLOGY
(2019)
Meeting Abstract
Oncology
M. Stasenko, I. U. Tunnage, C. W. Ashley, M. Rubinstein, J. J. Mueller, M. M. Leitao, V. Makker, C. F. Friedman, R. A. Soslow, D. M. Hyman, A. J. Latham, B. Weigelt, C. A. Aghajanian, N. R. Abu-Rustum, K. A. Cadoo
GYNECOLOGIC ONCOLOGY
(2019)
Article
Oncology
Ying L. Liu, Qin Zhou, Alexia Iasonos, Vivian N. Emengo, Claire Friedman, Jason A. Konner, Roisin E. O'Cearbhaill, Carol Aghajanian, Dmitriy Zamarin
GYNECOLOGIC ONCOLOGY
(2019)
Article
Oncology
Marina Stasenko, Irina Tunnage, Charles W. Ashley, Maria M. Rubinstein, Alicia J. Latham, Arnaud Da Cruz Paula, Jennifer J. Mueller, Mario M. Leitao, Claire E. Friedman, Vicky Makrke, Robert A. Soslow, Deborah F. DeLair, David M. Hyman, Dimitriy Zamarin, Kaled M. Alektiar, Carol A. Aghajanian, Nadeem R. Abu-Rustum, Britta Weigelt, Karen A. Cadoo
GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
Ana Oaknin, Claire F. Friedman, Lynda D. Roman, Anishka D'Souza, Irene Brana, Francois-Clement Bidard, Jonathan Goldman, Edwin A. Alvarez, Valentina Boni, Adam C. ElNaggar, Rodolfo Passalacqua, Khanh T. M. Do, Alessandro D. Santin, Kiana Keyvanjah, Feng Xu, Lisa D. Eli, Alshad S. Lalani, Richard P. Bryce, David M. Hyman, Funda Meric-Bernstam, David B. Solit, Bradley J. Monk
GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
Julia L. Boland, Qin Zhou, Alexia E. Iasonos, Roisin E. O'Cearbhaill, Jason Konner, Margaret Callahan, Claire Friedman, Carol Aghajanian, Paul Sabbatini, Dmitriy Zamarin, Karen A. Cadoo
GYNECOLOGIC ONCOLOGY
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jeeban P. Das, Michael A. Postow, Claire F. Friedman, Richard K. Do, Darragh F. Halpenny
EUROPEAN JOURNAL OF RADIOLOGY
(2020)
Article
Multidisciplinary Sciences
Harini Veeraraghavan, Claire F. Friedman, Deborah F. DeLair, Josip Nincevic, Yuki Himoto, Silvio G. Bruni, Giovanni Cappello, Iva Petkovska, Stephanie Nougaret, Ines Nikolovski, Ahmet Zehir, Nadeem R. Abu-Rustum, Carol Aghajanian, Dmitriy Zamarin, Karen A. Cadoo, Luis A. Diaz, Mario M. Leitao, Vicky Makker, Robert A. Soslow, Jennifer J. Mueller, Britta Weigelt, Yulia Lakhman
SCIENTIFIC REPORTS
(2020)
Article
Oncology
Claire F. Friedman, Alexandra Snyder Charen, Qin Zhou, Michael A. Carducci, Alexandre Buckley De Meritens, Bradley R. Corr, Siqing Fu, Travis J. Hollmann, Alexia Iasonos, Jason A. Konner, Panagiotis A. Konstantinopoulos, Susan C. Modesitt, Elad Sharon, Carol Aghajanian, Dmitriy Zamarin
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Article
Oncology
Maria M. Rubinstein, Rachel N. Grisham, Karen Cadoo, Chrisann Kyi, William P. Tew, Claire F. Friedman, Roisin E. O'Cearbhaill, Dmitriy Zamarin, Qin Zhou, Alexia Iasonos, Ines Nikolovski, Hongmei Xu, Krysten N. Soldan, Imogen Caird, Madhuri Martin, Joyce Guillen, Khalil T. Eid, Carol Aghajanian, Vicky Makker
Summary: The study evaluated the safety and tolerability of combination therapy with Selinexor and CP in advanced ovarian and endometrial cancers, showing promising efficacy. The most common treatment-related adverse events included thrombocytopenia, leukopenia, and hyperglycemia.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Ying L. Liu, Pier Selenica, Qin Zhou, Alexia Iasonos, Margaret Callahan, Noah Z. Feit, Julia Boland, Ignacio Vazquez-Garcia, Diana Mandelker, Ahmet Zehir, Robert A. Burger, Daniel J. Powell, Claire Friedman, Karen Cadoo, Rachel Grisham, Jason A. Konner, Roisin E. O'Cearbhaill, Carol Aghajanian, Jorge S. Reis-Filho, Britta Weigelt, Dmitriy Zamarin
JCO PRECISION ONCOLOGY
(2020)
Article
Oncology
Tara E. Soumerai, Mark T. A. Donoghue, Chaitanya Bandlamudi, Preethi Srinivasan, Matthew T. Chang, Dmitriy Zamarin, Karen A. Cadoo, Rachel N. Grisham, Roisin E. O'Cearbhaill, William P. Tew, Jason A. Konner, Martee L. Hensley, Vicky Makker, Paul Sabbatini, David R. Spriggs, Tiffany A. Troso-Sandoval, Alexandra Snyder Charen, Claire Friedman, Mila Gorsky, Sarah J. Schweber, Sumit Middha, Rajmohan Murali, Sarah Chiang, Kay J. Park, Robert A. Soslow, Marc Ladanyi, Bob T. Li, Jennifer Mueller, Britta Weigelt, Ahmet Zehir, Michael F. Berger, Nadeem R. Abu-Rustum, Carol Aghajanian, Deborah F. DeLair, David B. Solit, Barry S. Taylor, David M. Hyman
CLINICAL CANCER RESEARCH
(2018)
